Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Irinotecan"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 1647
Tytuł:
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Autorzy:
Zou L; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.; Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
Li X; Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.; Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
Wu X; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
Cui J; Department of Medical Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai, 200127, China.
Cui X; Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.; Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
Song X; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
Ren T; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
Han X; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
Zhu Y; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
Li H; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
Wu W; Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.; Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
Wang X; Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.; Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
Gong W; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China.
Wang L; Department of Medical Oncology, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai, 200127, China. .
Li M; Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. .; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China. .
Lau WY; Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. .
Liu Y; Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. .; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China. .; Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Jul 16; Vol. 21 (1), pp. 818. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cholangiocarcinoma/*drug therapy
Deoxycytidine/*analogs & derivatives
Oxaliplatin/*therapeutic use
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cholangiocarcinoma/pathology ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/pharmacology ; Irinotecan/therapeutic use ; Leucovorin/pharmacology ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Oxaliplatin/pharmacology ; Retrospective Studies ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
Autorzy:
Yoo C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Han B; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Kim HS; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Kim KP; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim D; Asan Institute for Life Science, University of Ulsan College of Medicine, Seoul, Korea.; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jeong JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim TW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim JH; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Choi DR; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Ha HI; Department of Radiology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Seo J; Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Chang HM; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Zang DY; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2018 Oct; Vol. 50 (4), pp. 1324-1330. Date of Electronic Publication: 2018 Jan 08.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Biliary Tract Neoplasms/*drug therapy
Irinotecan/*administration & dosage
Oxaliplatin/*administration & dosage
Oxonic Acid/*administration & dosage
Tegafur/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biliary Tract Neoplasms/genetics ; Drug Administration Schedule ; Drug Combinations ; Female ; Humans ; Irinotecan/therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis ; Oxaliplatin/therapeutic use ; Oxonic Acid/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics ; Tegafur/therapeutic use ; Treatment Outcome ; Tumor Suppressor Protein p53/genetics ; Exome Sequencing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients.
Autorzy:
He M; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Sun J; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Zhao D; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
He H; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Wang B; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Xu L; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Shang Y; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Ren S; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Zhang Y; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Wu T; a Department of Oncology , Second Affiliated Hospital of Dalian Medical University , Dalian , PR China.
Pokaż więcej
Źródło:
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group [Int J Hyperthermia] 2019; Vol. 36 (1), pp. 394-402. Date of Electronic Publication: 2019 Mar 27.
Typ publikacji:
Journal Article
MeSH Terms:
Fluorouracil/*therapeutic use
Irinotecan/*therapeutic use
Oxaliplatin/*therapeutic use
Pancreatic Neoplasms/*drug therapy
Pancreatic Neoplasms/*therapy
Aged ; China ; Female ; Fluorouracil/pharmacology ; Humans ; Hyperthermia, Induced ; Irinotecan/pharmacology ; Male ; Middle Aged ; Oxaliplatin/pharmacology ; Pancreatic Neoplasms/pathology ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Autorzy:
Vidra R; Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology Cluj- Napoca, Romania. .
Bodea R; Regional Institute of Gastroenterology and Hepatology Cluj- Napoca, Romania. .
Mercea V; Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca; Regional Institute of Gastroenterology and Hepatology Cluj- Napoca, Romania. .
Nemes A; Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca; Oncology Institute Cluj-Napoca, Romania. adina_.
Pokaż więcej
Źródło:
Journal of gastrointestinal and liver diseases : JGLD [J Gastrointestin Liver Dis] 2020 Jun 04; Vol. 29 (2), pp. 273-275. Date of Electronic Publication: 2020 Jun 04.
Typ publikacji:
Letter
MeSH Terms:
Betacoronavirus*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Capecitabine/*therapeutic use
Coronavirus Infections/*prevention & control
Deoxycytidine/*analogs & derivatives
Oxaliplatin/*therapeutic use
Pancreatic Neoplasms/*drug therapy
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Aged ; Antineoplastic Agents/therapeutic use ; COVID-19 ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Romania ; SARS-CoV-2 ; Gemcitabine
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Autorzy:
Frerker, Bernd (AUTHOR)
Bock, Felix (AUTHOR)
Cappel, Marie-Louise (AUTHOR)
Kriesen, Stephan (AUTHOR)
Klautke, Gunther (AUTHOR)
Hildebrandt, Guido (AUTHOR)
Manda, Katrin (AUTHOR)
Pokaż więcej
Źródło:
International Journal of Molecular Sciences. Jun2023, Vol. 24 Issue 12, p10385. 19p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.
Autorzy:
Huang, Ming-Yii (AUTHOR)
Huang, Yi-Jung (AUTHOR)
Cheng, Tian-Lu (AUTHOR)
Jhang, Wun-Ya (AUTHOR)
Ke, Chien-Chih (AUTHOR)
Chen, Yi-Ting (AUTHOR)
Kuo, Shih-Hsun (AUTHOR)
Lin, I-Ling (AUTHOR)
Huang, Yu-Hsiang (AUTHOR)
Chuang, Chih-Hung (AUTHOR)
Pokaż więcej
Źródło:
Cells (2073-4409). Jun2023, Vol. 12 Issue 11, p1475. 18p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Characterization of Kaolinite Single Methoxy Nano-Sheets as Potential Carriers of Oxaliplatin Drug of Enhanced Loading, Release, and Cytotoxicity Properties During the Treatment of Colorectal Cancer.
Autorzy:
Alqahtani, Mashael D. (AUTHOR)
Nasser, Nourhan (AUTHOR)
AlZahrani, Saleha A. (AUTHOR)
Allam, Ahmed A. (AUTHOR)
Abukhadra, Mostafa R. (AUTHOR)
Pokaż więcej
Źródło:
Journal of Inorganic & Organometallic Polymers & Materials. Jul2023, Vol. 33 Issue 7, p2111-2126. 16p.
Czasopismo naukowe
Szczegóły
Tytuł:
Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies.
Autorzy:
Tarpgaard, Line Schmidt
Winther, Stine Brændegaard
Pfeiffer, Per
Pokaż więcej
Temat:
NEOVASCULARIZATION inhibitors
GENETIC mutation
METASTASIS
IRINOTECAN
COLORECTAL cancer
CANCER patients
RANDOMIZED controlled trials
FLUOROURACIL
OXALIPLATIN
Źródło:
Cancers; Jan2024, Vol. 16 Issue 1, p126, 15p
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens.
Autorzy:
Tavakoli Pirzaman, Ali
Ebrahimzadeh Pirshahid, Manijeh
Babajani, Bahareh
Rahmati, Amirhossein
Niknezhad, Shokat
Hosseinzadeh, Rezvan
Taheri, Mehdi
Ebrahimi-Zadeh, Faezeh
Doostmohamadian, Shahrbanoo
Kazemi, Sohrab
Pokaż więcej
Temat:
CANCER cells
PTEN protein
MICRORNA
IRINOTECAN
NON-coding RNA
GASTROINTESTINAL cancer
Źródło:
Technology in Cancer Research & Treatment; 10/17/2023, p1-14, 14p
Czasopismo naukowe
Szczegóły
Tytuł:
The mechanism of antiproliferative activity of the oxaliplatin pyrophosphate derivative involves its binding to nuclear DNA in cancer cells.
Autorzy:
Prachařová, Jitka
Kostrhunová, Hana
Barbanente, Alessandra
Margiotta, Nicola
Brabec, Viktor
Pokaż więcej
Temat:
NUCLEAR DNA
CANCER cells
OXALIPLATIN
DNA damage
ANTINEOPLASTIC agents
IRINOTECAN
Źródło:
Journal of Biological Inorganic Chemistry (JBIC); Oct2023, Vol. 28 Issue 7, p669-678, 10p
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 1647

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies